Loading stock data…
$107.02+0.34 (+0.32%)
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Kymera Therapeutics, Inc. in the Healthcare sector is trading at $107.02 with a market capitalization of $9.2B. Wall Street consensus targets $139.35 (23 analysts), implying a +30.2% move over the next 12 months. The stock is currently 18% below its 52-week high of $130.05, remaining 13.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $65.00M↑ | $34.37M↑ | $2.87M↑ | $2.76M↓ | $11.48M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$75.61M↑ | -$84.15M↑ | -$97.90M↓ | -$88.67M↓ | -$84.56M |
| Net Income | -$61.21M↑ | -$69.23M↑ | -$86.98M↓ | -$82.17M↓ | -$76.61M |
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system...